东南大学附属中大医院介入与血管外科在我国介入放射领域中排名第一，学科带头人为中国科学院院士、中国医师协会介入医师分会会长、东南大学附属中大医院院长滕皋军教授。科室拥有国家临床重点专科，国家卫健委、中国医师协会等国家级培训基地。牵头制订了一系列国内外介入治疗规范，培训了全国3000余名介入医师，于2008、2011、2016三次荣获国家科技进步二等奖。
科室拥有介入手术专用高精尖设备数十台，是国内外同类科室中装备最精良和齐备的学科之一；科室首创国际/国内数十项介入新技术，如125I放射粒子支架技术、多电极动脉消融技术等；国内率先开展了椎体成形术、腰椎间盘介入治疗、主动脉夹层的介入治疗。迄今，已完成各类介入手术10万余例次，年手术量达7000台次，其中一半以上为全国各地疑难病症。

1.国家重点研发计划分中心子课题 （2019）

2.中国博士后基金面上项目（2022）

3.  国家自然科学基金青年基金（2020）

4. 江苏省重点研发计划面上项目（2022）

5.江苏省自然基金青年基金 （2019）

6.江苏省高层次人才青年资助项目（2022）

7.江苏省高等教育学会教育改革项目 （2021）

8.东南大学优秀青年教师科学研究（2021）

9.东南大学附属中大医院培育计划（2019）

代表性论文

1.Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west Lancet Gastroenterol Hepatol. 2019 Sep;4(9):721-730
2.Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial Journal of Hepatology, 2018.05, 68(5): 970~977
3.Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO) Hepatobiliary Surg Nutr. 2021 Oct;10(5):661-671.
4.A Novel Tracheobronchial Stent Loaded with I-125 Seeds in Patients with Malignant Airway Obstruction Compared to a Conventional Stent: A Prospective Randomized Controlled Study EBioMedicine, 2018.07, 33: 269~275
5.Palliative treatment with radiation-emitting metallic stents in unresectable Bismuth type III or IV hilar cholangiocarcinoma ESMO Open, 2017.9, 2(4): 0~e000242
6.Safety and Efficacy of Irradiation Stent Placement for Malignant Portal Vein Thrombus Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience Journal of Vascular and Interventional Radiology, 2017.06, 28(6): 786~794
7.Embolotherapy of unresectable hepatocellular carcinoma: Eastern perspective Chin Clin Oncol. 2019 Dec 9. pii: cco.2019.11.01
8.Radiomics Facilitates Candidate Selection for Irradiation Stents Among Patients With Unresectable Pancreatic Cancer Front Oncol. 2019 Sep 27;9:973
9.Oligorecurrence Non-Small Cell Lung Cancer after Failure of First-Line Chemotherapy: CT-guided 125I Seed Implantation versus Second-Line Chemotherapy Front Oncol. 2020 Apr 15;10:470
10.Risk Prediction for Early Biliary Infection after Percutaneous Transhepatic Biliary Stent Placement in Malignant Biliary Obstruction J Vasc Interv Radiol. 2019 Aug; 30(8):1233-1241. e1
11.COVID-19: What Should Interventional Radiologists Know and What Can They Do? J Vasc Interv Radiol . 2020 Jun;31(6):876-881

12.Early Warning Models to Estimate the 30-Day Mortality Risk After Stent Placement for Patients with Malignant Biliary ObstructionCardiovasc Intervent Radiol. 2019 Dec;42(12):1751-1759
13.Computed tomography-magnetic resonance imaging fusion-guided iodine-125 seed implantation for single malignant brain tumor: Feasibility and safetyJ Cancer Res Ther. 2019;15(4):818-824
14.Interventional radiology under era of COVID-19：Recommendations from Chinese College of Interventionalists. J Cancer Res Ther. 2020 Sep;16(5):974-978 
15.Portal Vein Irradiation Stent Plus Chemoembolization versus External Radiotherapy Plus Chemoembolization in Hepatocellular Carcinoma with Portal Vein Tumour Thrombus: A Retrospective Study. Cardiovasc Intervent Radiol. 2021 Sep;44(9):1414-1422
16.Tumor oxygenation nanoliposome synergistic hypoxia-inducible-factor-1 inhibitor enhanced Iodine-125 seed brachytherapy for esophageal cancer. Biomaterials. 2022 Oct;289:121801
17.Efficacy and safety of CT-guided 125I brachytherapy as the salvage treatment for locoregional lymph node recurrence of esophageal cancer. J Vasc Interv Radiol. 2022 Jul 18;S1051-0443(22)01073-9

18.Irradiation Stent with 125I Plus TACE versus Sorafenib Plus TACE for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A

Multicenter Randomized Trial.Int J Surg.2023 May 1;109(5):1188-1198

19.TAGNet: A transformer-based axial guided network for bile duct segmentation.Biomedical Signal Processing and Control 86 (2023) 105244.

20.A Novel Neutrophil-to-Lymphocyte Ratio and Sarcopenia Based TACE-Predict Model of Hepatocellular Carcinoma Patients.J Hepatocell Carcinoma

. 2023 Apr 20:10:659-671